Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Implications of Epigenetic Drift in Colorectal Neoplasia.

Luebeck GE, Hazelton WD, Curtius K, Maden SK, Yu M, Carter KT, Burke W, Lampe PD, Li CI, Ulrich CM, Newcomb PA, Westerhoff M, Kaz AM, Luo Y, Inadomi JM, Grady WM.

Cancer Res. 2019 Feb 1;79(3):495-504. doi: 10.1158/0008-5472.CAN-18-1682. Epub 2018 Oct 5.

PMID:
30291105
2.

Re: Think before you leap.

Han SS, Ten Haaf K, Hazelton WD, Jeon J, Meza R, Kong CY, Feuer EJ, de Koning HJ, Plevritis SK.

Int J Cancer. 2018 Apr 1;142(7):1507-1509. doi: 10.1002/ijc.31183. Epub 2017 Dec 28. No abstract available.

PMID:
29194597
3.

Identification of a key role of widespread epigenetic drift in Barrett's esophagus and esophageal adenocarcinoma.

Luebeck EG, Curtius K, Hazelton WD, Maden S, Yu M, Thota PN, Patil DT, Chak A, Willis JE, Grady WM.

Clin Epigenetics. 2017 Oct 16;9:113. doi: 10.1186/s13148-017-0409-4. eCollection 2017.

4.

Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device.

Heberle CR, Omidvari AH, Ali A, Kroep S, Kong CY, Inadomi JM, Rubenstein JH, Tramontano AC, Dowling EC, Hazelton WD, Luebeck EG, Lansdorp-Vogelaar I, Hur C.

Clin Gastroenterol Hepatol. 2017 Sep;15(9):1397-1404.e7. doi: 10.1016/j.cgh.2017.02.017. Epub 2017 Feb 24.

5.

Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis.

Kroep S, Heberle CR, Curtius K, Kong CY, Lansdorp-Vogelaar I, Ali A, Wolf WA, Shaheen NJ, Spechler SJ, Rubenstein JH, Nishioka NS, Meltzer SJ, Hazelton WD, van Ballegooijen M, Tramontano AC, Gazelle GS, Luebeck EG, Inadomi JM, Hur C.

Clin Gastroenterol Hepatol. 2017 Sep;15(9):1471-1474. doi: 10.1016/j.cgh.2016.12.034. Epub 2017 Jan 12. No abstract available.

6.

The impact of overdiagnosis on the selection of efficient lung cancer screening strategies.

Han SS, Ten Haaf K, Hazelton WD, Munshi VN, Jeon J, Erdogan SA, Johanson C, McMahon PM, Meza R, Kong CY, Feuer EJ, de Koning HJ, Plevritis SK.

Int J Cancer. 2017 Jun 1;140(11):2436-2443. doi: 10.1002/ijc.30602.

7.

A Molecular Clock Infers Heterogeneous Tissue Age Among Patients with Barrett's Esophagus.

Curtius K, Wong CJ, Hazelton WD, Kaz AM, Chak A, Willis JE, Grady WM, Luebeck EG.

PLoS Comput Biol. 2016 May 11;12(5):e1004919. doi: 10.1371/journal.pcbi.1004919. eCollection 2016 May. Erratum in: PLoS Comput Biol. 2017 Mar 17;13(3):e1005439.

8.

A Multiscale Model Evaluates Screening for Neoplasia in Barrett's Esophagus.

Curtius K, Hazelton WD, Jeon J, Luebeck EG.

PLoS Comput Biol. 2015 May 22;11(5):e1004272. doi: 10.1371/journal.pcbi.1004272. eCollection 2015 May.

9.

The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma.

Hazelton WD, Curtius K, Inadomi JM, Vaughan TL, Meza R, Rubenstein JH, Hur C, Luebeck EG.

Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1012-23. doi: 10.1158/1055-9965.EPI-15-0323-T. Epub 2015 Apr 30.

10.

Incremental benefits of screening colonoscopy over sigmoidoscopy in average-risk populations: a model-driven analysis.

Jeon J, Meza R, Hazelton WD, Renehan AG, Luebeck EG.

Cancer Causes Control. 2015 Jun;26(6):859-70. doi: 10.1007/s10552-015-0559-7. Epub 2015 Mar 18.

11.

Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling.

Kong CY, Kroep S, Curtius K, Hazelton WD, Jeon J, Meza R, Heberle CR, Miller MC, Choi SE, Lansdorp-Vogelaar I, van Ballegooijen M, Feuer EJ, Inadomi JM, Hur C, Luebeck EG.

Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):997-1006. doi: 10.1158/1055-9965.EPI-13-1233. Epub 2014 Apr 1.

12.

Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.

Meza R, ten Haaf K, Kong CY, Erdogan A, Black WC, Tammemagi MC, Choi SE, Jeon J, Han SS, Munshi V, van Rosmalen J, Pinsky P, McMahon PM, de Koning HJ, Feuer EJ, Hazelton WD, Plevritis SK.

Cancer. 2014 Jun 1;120(11):1713-24. doi: 10.1002/cncr.28623. Epub 2014 Feb 27.

13.

Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force.

de Koning HJ, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, Erdogan SA, Kong CY, Han SS, van Rosmalen J, Choi SE, Pinsky PF, Berrington de Gonzalez A, Berg CD, Black WC, Tammem├Ągi MC, Hazelton WD, Feuer EJ, McMahon PM.

Ann Intern Med. 2014 Mar 4;160(5):311-20. doi: 10.7326/M13-2316.

14.

Impact of tumor progression on cancer incidence curves.

Luebeck EG, Curtius K, Jeon J, Hazelton WD.

Cancer Res. 2013 Feb 1;73(3):1086-96. doi: 10.1158/0008-5472.CAN-12-2198. Epub 2012 Oct 10.

15.

Chapter 8: The FHCRC lung cancer model.

Hazelton WD, Jeon J, Meza R, Moolgavkar SH.

Risk Anal. 2012 Jul;32 Suppl 1:S99-S116. doi: 10.1111/j.1539-6924.2011.01681.x.

16.

Chapter 13: CISNET lung models: comparison of model assumptions and model structures.

McMahon PM, Hazelton WD, Kimmel M, Clarke LD.

Risk Anal. 2012 Jul;32 Suppl 1:S166-78. doi: 10.1111/j.1539-6924.2011.01714.x.

17.

Longitudinal multistage model for lung cancer incidence, mortality, and CT detected indolent and aggressive cancers.

Hazelton WD, Goodman G, Rom WN, Tockman M, Thornquist M, Moolgavkar S, Weissfeld JL, Feng Z.

Math Biosci. 2012 Nov;240(1):20-34. doi: 10.1016/j.mbs.2012.05.008. Epub 2012 Jun 15.

18.

Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000.

Moolgavkar SH, Holford TR, Levy DT, Kong CY, Foy M, Clarke L, Jeon J, Hazelton WD, Meza R, Schultz F, McCarthy W, Boer R, Gorlova O, Gazelle GS, Kimmel M, McMahon PM, de Koning HJ, Feuer EJ.

J Natl Cancer Inst. 2012 Apr 4;104(7):541-8. doi: 10.1093/jnci/djs136. Epub 2012 Mar 14.

19.

Body mass, tobacco smoking, alcohol drinking and risk of cancer of the small intestine--a pooled analysis of over 500,000 subjects in the Asia Cohort Consortium.

Boffetta P, Hazelton WD, Chen Y, Sinha R, Inoue M, Gao YT, Koh WP, Shu XO, Grant EJ, Tsuji I, Nishino Y, You SL, Yoo KY, Yuan JM, Kim J, Tsugane S, Yang G, Wang R, Xiang YB, Ozasa K, Nagai M, Kakizaki M, Chen CJ, Park SK, Shin A, Ahsan H, Qu CX, Lee JE, Thornquist M, Rolland B, Feng Z, Zheng W, Potter JD.

Ann Oncol. 2012 Jul;23(7):1894-8. doi: 10.1093/annonc/mdr562. Epub 2011 Dec 6.

20.

Biomarker-based early cancer detection: is it achievable?

Hazelton WD, Luebeck EG.

Sci Transl Med. 2011 Nov 16;3(109):109fs9. doi: 10.1126/scitranslmed.3003272.

21.

Analysis of lung cancer incidence in the Nurses' Health and the Health Professionals' Follow-Up Studies using a multistage carcinogenesis model.

Meza R, Hazelton WD, Colditz GA, Moolgavkar SH.

Cancer Causes Control. 2008 Apr;19(3):317-28. Epub 2007 Dec 6.

PMID:
18058248
22.

Biologically based analysis of lung cancer incidence in a large Canadian occupational cohort with low-dose ionizing radiation exposure, and comparison with Japanese atomic bomb survivors.

Hazelton WD, Moolgavkar SH, Curtis SB, Zielinski JM, Ashmore JP, Krewski D.

J Toxicol Environ Health A. 2006 Jun;69(11):1013-38.

PMID:
16840251
23.

Multistage carcinogenesis and lung cancer mortality in three cohorts.

Hazelton WD, Clements MS, Moolgavkar SH.

Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1171-81.

24.

A Michaelis-Menten-style model for the autocatalytic enzyme prostaglandin H synthase.

Tien JH, Hazelton WD, Sparks R, Ulrich CM.

Bull Math Biol. 2005 Jul;67(4):683-700.

PMID:
15893548
25.

From mechanisms to risk estimation--bridging the chasm.

Curtis SB, Hazelton WD, Luebeck EG, Moolgavkar SH.

Adv Space Res. 2004;34(6):1404-9.

PMID:
15881782
26.

Prostaglandin H synthases: members of a class of quasi-linear threshold switches.

Hazelton WD, Tien JH, Donato VW, Sparks R, Ulrich CM.

Biochem Pharmacol. 2004 Aug 1;68(3):423-32.

PMID:
15242809
27.

Response to the commentary of Donald A. Pierce (Radiat. Res. 160, 718-723, 2003).

Heidenreich WF, Luebeck EG, Hazelton WD, Paretzke HG, Moolgavkar SH.

Radiat Res. 2004 Mar;161(3):369-70; author reply 370-1. No abstract available.

PMID:
14982477
28.

The use of biologically based cancer risk models in radiation epidemiology.

Krewski D, Zielinski JM, Hazelton WD, Garner MJ, Moolgavkar SH.

Radiat Prot Dosimetry. 2003;104(4):367-76. Review.

PMID:
14579893
29.

A new perspective of carcinogenesis from protracted high-LET radiation arises from the two-stage clonal expansion model.

Curtis SB, Luebeck EG, Hazelton WD, Moolgavkar SH.

Adv Space Res. 2002;30(4):937-44.

PMID:
12539762
30.

Multistage carcinogenesis and radiation.

Luebeck EG, Hazelton WD.

J Radiol Prot. 2002 Sep;22(3A):A43-9.

PMID:
12400946
31.

Multistage models and the incidence of cancer in the cohort of atomic bomb survivors.

Heidenreich WF, Luebeck EG, Hazelton WD, Paretzke HG, Moolgavkar SH.

Radiat Res. 2002 Nov;158(5):607-14.

PMID:
12385638
32.

The role of promotion in carcinogenesis from protracted high-LET exposure.

Curtis SB, Luebeck EG, Hazelton WD, Moolgavkar SH.

Phys Med. 2001;17 Suppl 1:157-60.

PMID:
11771544
34.

The importance of promotion in lung carcinogenesis for protracted exposures to radon and radon progeny.

Luebeck EG, Curtis SB, Hazelton WD, Moolgavkar SH.

Radiat Res. 2000 Dec;154(6):730;discussion 730-1. No abstract available.

PMID:
11187018
35.

Biologically based analysis of the data for the Colorado uranium miners cohort: age, dose and dose-rate effects.

Luebeck EG, Heidenreich WF, Hazelton WD, Paretzke HG, Moolgavkar SH.

Radiat Res. 1999 Oct;152(4):339-51.

PMID:
10477911

Supplemental Content

Loading ...
Support Center